Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Corp (CELG)

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,834,552
  • Shares Outstanding, K 705,260
  • Annual Sales, $ 15,281 M
  • Annual Income, $ 4,046 M
  • 60-Month Beta 1.45
  • Price/Sales 4.26
  • Price/Cash Flow 10.41
  • Price/Book 7.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 2.45
  • Number of Estimates 2
  • High Estimate 2.56
  • Low Estimate 2.34
  • Prior Year 1.86
  • Growth Rate Est. (year over year) +31.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
91.61 +0.16%
on 07/15/19
98.97 -7.29%
on 06/21/19
-4.75 (-4.92%)
since 06/14/19
3-Month
91.61 +0.16%
on 07/15/19
98.97 -7.29%
on 06/21/19
-3.34 (-3.51%)
since 04/15/19
52-Week
58.59 +56.61%
on 12/26/18
98.97 -7.29%
on 06/21/19
+6.07 (+7.08%)
since 07/13/18

Most Recent Stories

More News
J&J Submits BLA for Subcutaneous Formulation of Darzalex

Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

CELG : 91.76 (-0.18%)
JNJ : 134.71 (+0.31%)
RHHBY : 33.5500 (+0.63%)
TAK : 17.99 (+1.12%)
Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

Celgene (CELG) closed at $91.76 in the latest trading session, marking a -0.18% move from the prior day.

CELG : 91.76 (-0.18%)
Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?

Bristol-Myers (BMY) declines on uncertainty and delay of the Celgene merger.

CELG : 91.76 (-0.18%)
MRK : 80.96 (+1.54%)
RHHBY : 33.5500 (+0.63%)
BMY : 44.19 (-0.18%)
Celgene Corp Falls 1.62% on Heavy Volume: Watch For Potential Rebound

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $91.98 to a high of $93.45. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $92.96...

CELG : 91.76 (-0.18%)
After Yesterday's Decline of 1.62%, Celgene Corp Offers Investors Better Value

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $91.98 to a high of $93.45. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $92.96...

CELG : 91.76 (-0.18%)
FDA Accepts Sanofi's BLA for Myeloma Candidate to Review

The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.

CELG : 91.76 (-0.18%)
MRK : 80.96 (+1.54%)
REGN : 298.20 (+1.93%)
SNY : 41.65 (+0.90%)
Will Patent Woes Boost Pharma Stock Megamergers Further?

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

CELG : 91.76 (-0.18%)
AGN : 166.08 (+0.14%)
ABBV : 70.27 (-0.01%)
GILD : 68.07 (+2.73%)
AMGN : 176.12 (+0.68%)
BMY : 44.19 (-0.18%)
BIIB : 233.62 (+0.95%)
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Celgene (CELG) closed at $93.81, marking a +0.57% move from the previous day.

CELG : 91.76 (-0.18%)
Celgene Corp (CELG) Crosses Pivot Point Support at $93.48

Shares of Celgene Corp (NASDAQ:CELG) have bearishly opened below the pivot of $93.89 today and have reached the first support level of $93.48. Should the shares continue to fall, the support pivots of...

CELG : 91.76 (-0.18%)
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.

CELG : 91.76 (-0.18%)
AGN : 166.08 (+0.14%)
EDIT : 25.30 (+1.81%)
NTLA : 16.78 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 92.45
1st Resistance Point 92.10
Last Price 91.76
1st Support Level 91.51
2nd Support Level 91.27

See More

52-Week High 98.97
Last Price 91.76
Fibonacci 61.8% 83.54
Fibonacci 50% 78.78
Fibonacci 38.2% 74.02
52-Week Low 58.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar